---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-048426"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T05:59:55.514379+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q4/FY2024 results; cash at $454.7M; HCV Phase 3 starts April 2025

## Summary
- Net loss per share Q4 2024 improved to ($0.40) from ($0.47); full year net loss per share ($2.00) vs ($1.63).
- Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024 vs $578.1M year earlier.
- Successful End-of-Phase 2 FDA meeting for HCV regimen bemnifosbuvir/ruzasvir; Phase 3 enrollment expected April 2025.
- Reduced workforce by 25% in Q1 2025 to achieve ~$15M in cost savings through 2027.
- Engaged Evercore for strategic partnerships for HCV Phase 3 program; appointed Arthur S. Kirsch to board.

## SEC filing metadata
- accession: 0001193125-25-048426
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/0001193125-25-048426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/d925111d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-048426
- JSON: https://secwatch.observer/filing/0001193125-25-048426.json
- Plain text: https://secwatch.observer/filing/0001193125-25-048426.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.